NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Forecast, Price & News

$0.89

+0.08 (+9.88%)

(As of 05/31/2023 ET)

Compare

Today's Range: $0.79
▼
$0.91
50-Day Range: $0.29
▼
$0.89
52-Week Range: $0.27
▼
$1.86

Volume: 1.67 million shs
Average Volume: 852,446 shs
Market Capitalization: $106.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.80

Leap Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 214.6% Upside
$2.80 Price Target
Short Interest: Bearish
9.65% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.63
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.57) to ($0.38) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

833rd out of 1,006 stocks

Pharmaceutical Preparations Industry

416th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Leap Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.80, Leap Therapeutics has a forecasted upside of 214.6% from its current price of $0.89.
Amount of Analyst Coverage
Leap Therapeutics has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.65% of the outstanding shares of Leap Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Leap Therapeutics has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
Change versus previous month
Short interest in Leap Therapeutics has recently increased by 0.09%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Leap Therapeutics does not currently pay a dividend.
Dividend Growth
Leap Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LPTX.

3.1

News and Social Media Coverage

News Sentiment
Leap Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Leap Therapeutics this week, compared to 1 article on an average week.
Search Interest
12 people have searched for LPTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
4 people have added Leap Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Leap Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
12.50% of the stock of Leap Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 37.44% of the stock of Leap Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Leap Therapeutics are expected to grow in the coming year, from ($0.57) to ($0.38) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Leap Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Leap Therapeutics is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Leap Therapeutics has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

May 29, 2023 | markets.businessinsider.com

Robert W. Baird Sticks to Their Buy Rating for Leap Therapeutics (LPTX)

May 26, 2023 | markets.businessinsider.com

Leap Therapeutics (LPTX) Receives a Buy from Mizuho Securities

June 1, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 17, 2023 | americanbankingnews.com

Equities Analysts Issue Forecasts for Leap Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:LPTX)

May 16, 2023 | msn.com

HC Wainwright & Co. Reiterates Leap Therapeutics (LPTX) Buy Recommendation

May 16, 2023 | markets.businessinsider.com

H.C. Wainwright Sticks to Its Buy Rating for Leap Therapeutics (LPTX)

May 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Leap Therapeutics (LPTX) and Jasper Therapeutics (JSPR)

May 15, 2023 | finance.yahoo.com

Leap Therapeutics Reports First Quarter 2023 Financial Results

June 1, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

April 13, 2023 | msn.com

Mizuho Reiterates Leap Therapeutics (LPTX) Buy Recommendation

April 12, 2023 | finance.yahoo.com

Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

April 4, 2023 | finance.yahoo.com

Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely

April 3, 2023 | americanbankingnews.com

Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update

March 31, 2023 | americanbankingnews.com

HC Wainwright Equities Analysts Reduce Earnings Estimates for Leap Therapeutics, Inc. (NASDAQ:LPTX)

March 30, 2023 | americanbankingnews.com

FY2027 Earnings Forecast for Leap Therapeutics, Inc. (NASDAQ:LPTX) Issued By HC Wainwright

March 27, 2023 | markets.businessinsider.com

What 5 Analyst Ratings Have To Say About Leap Therapeutics

March 26, 2023 | americanbankingnews.com

Leap Therapeutics (NASDAQ:LPTX) Announces Earnings Results

March 24, 2023 | markets.businessinsider.com

Mizuho Securities Remains a Buy on Leap Therapeutics (LPTX)

March 24, 2023 | finanznachrichten.de

Leap Therapeutics, Inc.: Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

March 24, 2023 | prnewswire.com

Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

March 20, 2023 | markets.businessinsider.com

Robert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX)

March 16, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Its Buy Rating for Leap Therapeutics (LPTX)

March 16, 2023 | finance.yahoo.com

Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

March 16, 2023 | uk.finance.yahoo.com

Leap Therapeutics, Inc. (LPTX)

January 25, 2023 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations

January 25, 2023 | finance.yahoo.com

Leap Therapeutics Shares Fall After Flame Biosciences Acquisition

January 24, 2023 | businesswire.com

LPTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Leap Therapeutics, Inc. Is Fair to Shareholders

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Company Calendar

Last Earnings: 5/15/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LPTX
CUSIP: N/A
CIK: 1509745
Web: www.leaptx.com
Phone: (617) 714-0360
Fax: N/A
Employees: 36
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.80
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +214.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.71)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-54,600,000.00
Net Margins: N/A
Pretax Margin: -14,214.93%
Return on Equity: -143.12%
Return on Assets: -97.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.15
Quick Ratio: 10.15

Sales & Book Value

Annual Sales: $1.50 million
Price / Sales: 70.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.24 per share
Price / Book: 3.71

Miscellaneous

Outstanding Shares: 119,410,000
Free Float: 104,485,000
Market Cap: $106.27 million
Optionable: Not Optionable
Beta: 0.74

Key Executives

Doug E. Onsi
President, CEO, CFO, Secretary & Treasurer

Augustine J. Lawlor
Chief Operating Officer

Cynthia Sirard
Chief Medical Officer

Jason S. Baum
Chief Scientific Officer

Michael Haas
Head-Research

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LPTX Stock - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings or view top-rated stocks.
What is Leap Therapeutics' stock price forecast for 2023?: 3 brokerages have issued 12 month price targets for Leap Therapeutics' shares. Their LPTX share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $2.80 in the next twelve months. This suggests a possible upside of 214.6% from the stock's current price.
View analysts price targets for LPTX or view top-rated stocks among Wall Street analysts.
How have LPTX shares performed in 2023?: Leap Therapeutics' stock was trading at $0.45 at the beginning of the year. Since then, LPTX shares have increased by 97.8% and is now trading at $0.89.
View the best growth stocks for 2023 here.
When is Leap Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our LPTX earnings forecast.
How were Leap Therapeutics' earnings last quarter?: Leap Therapeutics, Inc. (NASDAQ:LPTX) issued its quarterly earnings results on Monday, May, 15th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.23.
What other stocks do shareholders of Leap Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Allena Pharmaceuticals (ALNA), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Amarin (AMRN), OPKO Health (OPK), VYNE Therapeutics (VYNE), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB) and Rigel Pharmaceuticals (RIGL).

What is Leap Therapeutics' stock symbol?: Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
Who are Leap Therapeutics' major shareholders?: Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (6.22%), Samsara BioCapital LLC (5.61%), Price T Rowe Associates Inc. MD (1.29%), Key Client Fiduciary Advisors LLC (1.29%), Knott David M Jr (0.47%) and Renaissance Technologies LLC (0.38%).
View institutional ownership trends.
How do I buy shares of Leap Therapeutics?: Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Leap Therapeutics' stock price today?: One share of LPTX stock can currently be purchased for approximately $0.89.
How much money does Leap Therapeutics make?: Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $106.27 million and generates $1.50 million in revenue each year. The company earns $-54,600,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.
How can I contact Leap Therapeutics?: Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial